As a leader in heart valves for over 60 years, Edwards Lifesciences is dedicated to providing you a destination for the latest transcatheter heart valve information, tools, resources, and innovative solutions.

New PARTNER 3 trial 5 year data

Data from the PARTNER 3 trial continues to prove the Edwards SAPIEN 3 platform is the choice for lifetime management – from the index procedure and beyond.

  • Life: The only transcatheter heart valve with 1% death or disabling stroke at 1 year
  • Time: The only transcatheter heart valve with 90% survival at 5 years
  • Management: The only transcatheter heart valve with a THV-in-THV indication*

*For patients assessed at high-risk for surgical replacement.

Access the resource library

Whether you're preparing for an upcoming presentation or seeking tools to assist in daily practice, the resource library is always available to simplify the process. Browse the latest data, patient guides, best practices, and additional materials to help equip your Heart Team for success.

Get TAVI Resources

ACC/AHA Guideline expands TAVI as a Class I recommendation

The ACC/AHA released key updates in their 2020 Guideline for Valvular Heart Disease, including new recommendations for the treatment of severe symptomatic aortic stenosis and transcatheter valve repair/implantation for patients. Have these guidelines readily available for your team.

Your first-time valve choice today affects your patients' treatment options tomorrow1

As you expand TAVI to new patient populations, protecting the lifetime management of your patients becomes the new standard.

See the data

References:   1. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv. 2020; 13(21):2528-2538.